# A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma

> **NCT05121103** · PHASE1 · TERMINATED · sponsor: **Epizyme, Inc.** · enrollment: 13 (actual)

## Conditions studied

- Multiple Myeloma, Refractory
- Diffuse Large B-Cell Lymphoma
- Diffuse Large B Cell Lymphoma Refractory
- Multiple Myeloma in Relapse

## Interventions

- **DRUG:** EZM0414

## Key facts

- **NCT ID:** NCT05121103
- **Lead sponsor:** Epizyme, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-05-31
- **Primary completion:** 2024-04-30
- **Final completion:** 2024-04-30
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Strategic business decision
- **Last updated:** 2025-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05121103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05121103, "A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT05121103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*